JP2018530534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530534A5 JP2018530534A5 JP2018512945A JP2018512945A JP2018530534A5 JP 2018530534 A5 JP2018530534 A5 JP 2018530534A5 JP 2018512945 A JP2018512945 A JP 2018512945A JP 2018512945 A JP2018512945 A JP 2018512945A JP 2018530534 A5 JP2018530534 A5 JP 2018530534A5
- Authority
- JP
- Japan
- Prior art keywords
- allogeneic
- cell population
- configuration
- pharmaceutical composition
- human patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216525P | 2015-09-10 | 2015-09-10 | |
| US62/216,525 | 2015-09-10 | ||
| US201562220641P | 2015-09-18 | 2015-09-18 | |
| US62/220,641 | 2015-09-18 | ||
| PCT/US2016/050857 WO2017044678A1 (en) | 2015-09-10 | 2016-09-09 | Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530534A JP2018530534A (ja) | 2018-10-18 |
| JP2018530534A5 true JP2018530534A5 (https=) | 2019-11-28 |
| JP6947720B2 JP6947720B2 (ja) | 2021-10-13 |
Family
ID=57068181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512945A Expired - Fee Related JP6947720B2 (ja) | 2015-09-10 | 2016-09-09 | Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190381098A1 (https=) |
| EP (1) | EP3347028A1 (https=) |
| JP (1) | JP6947720B2 (https=) |
| KR (1) | KR20180048992A (https=) |
| CN (1) | CN108348552A (https=) |
| AU (1) | AU2016320877A1 (https=) |
| CA (1) | CA2997757A1 (https=) |
| HK (1) | HK1257882A1 (https=) |
| IL (1) | IL257929B2 (https=) |
| MX (1) | MX395106B (https=) |
| RU (1) | RU2743381C2 (https=) |
| TW (1) | TWI759270B (https=) |
| WO (1) | WO2017044678A1 (https=) |
| ZA (1) | ZA201801656B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217203A1 (en) | 2017-05-25 | 2018-11-29 | Oreilly Richard John | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| AU2018355145A1 (en) | 2017-10-23 | 2020-04-30 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| US20210000874A1 (en) | 2018-03-14 | 2021-01-07 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
| CN111643525A (zh) * | 2020-06-16 | 2020-09-11 | 济宁医学院 | 引发免疫排斥反应在肿瘤治疗中的应用及其方法 |
| CN113881632B (zh) * | 2021-09-29 | 2023-09-29 | 四川省医学科学院·四川省人民医院 | 一种提高dc细胞活性的细胞培养基及培养方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1560078B (zh) * | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
| ATE399179T1 (de) * | 1998-09-30 | 2008-07-15 | Corixa Corp | Zusammensetzungen und verfahren für wt1- spezifische immunotherapie |
| CN101580538B (zh) * | 2003-11-05 | 2013-06-19 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
| FR2931163B1 (fr) * | 2008-05-16 | 2013-01-18 | Ets Francais Du Sang | Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive |
| EP2365823B1 (en) * | 2008-10-30 | 2016-11-30 | Yeda Research And Development Company Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| CA2861206C (en) * | 2012-01-13 | 2021-07-06 | Richard J. O'reilly | Immunogenic wt-1 peptides and methods of use thereof |
-
2016
- 2016-09-09 KR KR1020187009368A patent/KR20180048992A/ko not_active Withdrawn
- 2016-09-09 AU AU2016320877A patent/AU2016320877A1/en not_active Abandoned
- 2016-09-09 EP EP16775897.8A patent/EP3347028A1/en not_active Withdrawn
- 2016-09-09 TW TW105129257A patent/TWI759270B/zh not_active IP Right Cessation
- 2016-09-09 JP JP2018512945A patent/JP6947720B2/ja not_active Expired - Fee Related
- 2016-09-09 CN CN201680064239.2A patent/CN108348552A/zh active Pending
- 2016-09-09 WO PCT/US2016/050857 patent/WO2017044678A1/en not_active Ceased
- 2016-09-09 CA CA2997757A patent/CA2997757A1/en active Pending
- 2016-09-09 HK HK19100243.4A patent/HK1257882A1/zh unknown
- 2016-09-09 RU RU2018112526A patent/RU2743381C2/ru active
- 2016-09-09 MX MX2018002816A patent/MX395106B/es unknown
- 2016-09-09 IL IL257929A patent/IL257929B2/en unknown
- 2016-09-09 US US15/758,566 patent/US20190381098A1/en not_active Abandoned
-
2018
- 2018-03-09 ZA ZA2018/01656A patent/ZA201801656B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530534A5 (https=) | ||
| Harimoto et al. | Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells | |
| JP2025092558A (ja) | 養子細胞療法のための改良型細胞培養方法 | |
| Schijns et al. | First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo-and auto-immune tumor reactivity | |
| Gao et al. | CD40‐deficient dendritic cells producing interleukin‐10, but not interleukin‐12, induce T‐cell hyporesponsiveness in vitro and prevent acute allograft rejection | |
| JP2018520095A5 (https=) | ||
| Wang et al. | Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs | |
| JP2019530449A5 (https=) | ||
| RU2017143151A (ru) | Способы лечения ассоциированных с вирусом эпштейна-барр лимфопролиферативных заболеваний при помощи t-клеточной терапии | |
| JP5916613B2 (ja) | 多発性骨髄腫細胞からの抗原ペプチドの同定 | |
| RU2018112526A (ru) | Способы лечения множественной миеломы и плазмоклеточного лейкоза посредством т-клеточной терапии | |
| Motta et al. | Applications of virus-specific T cell therapies post-BMT | |
| Arina et al. | Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1–resistant tumors leading to tumor eradication | |
| Northrop et al. | CD8+ T-cell memory: only the good ones last | |
| Liu et al. | Immune-based therapy clinical trials in hepatocellular carcinoma | |
| Jofra et al. | Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection | |
| Gea-Banacloche | Immunomodulation | |
| Tournier et al. | Chronic restraint stress induces severe disruption of the T‐cell specific response to tetanus toxin vaccine | |
| AU7987391A (en) | Enhancing the association of exogenous peptides with class 1 MHC molecules on immune system cells | |
| Kogo et al. | Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo | |
| CN105899219B (zh) | 人类免疫缺陷病毒/获得性免疫缺陷综合症的治疗 | |
| Rakhmilevich et al. | Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells | |
| Zeiser et al. | Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation | |
| US20070161108A1 (en) | Bob-1 specific T cells and methods to use | |
| JPWO2021081115A5 (https=) |